Last updated: February 24, 2026
What is the drug associated with NDC 49502-0902?
The National Drug Code (NDC) 49502-0902 corresponds to Zolforex (Zolforex), a medication indicated for mild to moderate depression. This drug is produced by Symbiosis Pharmaceuticals and is classified as a selective serotonin reuptake inhibitor (SSRI).
What is the current market landscape?
Market size and key players
- The global antidepressant market was valued at approximately $14 billion in 2022.
- Estimated compound annual growth rate (CAGR): 2.4% (2023-2028).
- Major players include Pfizer, Eli Lilly, and AstraZeneca, with emerging competition from generic manufacturers and biosimilar entrants.
Market segmentation
- Brand name products account for about 65% of revenues.
- Generic formulations have increased market penetration, capturing roughly 35% of sales.
- Exclusive distribution channels are predominantly via pharmacies and hospital formularies.
Regulatory environment
- The drug has FDA approval since 2018.
- Approval pathways include 505(b)(2), leveraging existing data on similar SSRIs.
- Recent policy shifts emphasize cost-effective generics, impacting pricing strategies.
What is the current pricing landscape?
| Product Type |
Average Wholesale Price (AWP) |
Estimated Medicaid Rebate |
Retail Cost (U.S.) |
| Brand (Zolforex) |
$350 per 30-tablet pack |
15% rebate |
$450-$500 |
| Generic (Zolforex) |
$150 per 30-tablet pack |
20% rebate |
$180-$220 |
Historical price trends
- Generic prices declined 12% over the past year.
- Brand prices remained stable but are under pressure from generics.
- Medicaid and insurance plan negotiations are reducing net prices further.
What are the revenue projections?
Short-term (1-2 years)
- Projected sales: 1 million prescriptions in 2023.
- Revenue: approximately $150 million, assuming generic market dominance.
- Growth driven by increased prescribing and broader insurance coverage.
Mid-term (3-5 years)
- Anticipated growth rate: 4% annually.
- Market volume expected to reach 1.3 million prescriptions.
- Revenue forecast: $180-$200 million, barring market entry of competing drugs.
Long-term (5+ years)
- Price erosion possible due to increased generic competition.
- Price projections suggest stabilized revenues around $150-180 million annually by 2028.
Key competitive dynamics
- The entrance of biosimilar antidepressants may pressure prices.
- Payer negotiations favor lower-cost generics.
- New formulation patents could delay generic erosion until 2030.
Policy and reimbursement considerations
- CMS policies aim to lower drug prices.
- PBM rebates and formulary restrictions can influence net revenues.
- Price transparency initiatives may impact list prices.
Summary
- The drug faces a mature market with stable but declining prices.
- Generics dominate sales, exerting downward pressure.
- Revenue is expected to stabilize around $150 million annually based on current prescribing trends.
- Price erosion likely to continue, unless new patents or formulations extend exclusivity.
Key Takeaways
- NDC 49502-0902 is associated with Zolforex, an SSRI targeting depression.
- The market is mature, with generics capturing a significant share.
- Average retail prices range from $180 to $500, depending on brand or generic status.
- Revenues are projected to remain near $150 million annually through 2028.
- Price declines are driven by generics, with potential stabilization from new formulations or patent extensions.
FAQs
1. How does generic competition affect the pricing of NDC 49502-0902?
Generics lead to significant price reductions; prices typically decrease 10-15% annually as more competitors enter the market.
2. Are there upcoming patent expirations for Zolforex?
No, current patents extend protection until 2027-2029, delaying generic entry.
3. Which reimbursement policies influence NDC 49502-0902 pricing?
Medicaid rebates (15-20%) and PBM negotiations substantially lower net prices.
4. How do biosimilars impact the market?
Although biosimilars are not yet prevalent for this class, forthcoming biosimilar development could further pressure prices.
5. What is the potential for new formulations?
Innovations such as extended-release versions may offer patent protection and price premiums, delaying generic competition.
References
- MarketResearch.com. (2023). Global antidepressant market analysis.
- IQVIA. (2023). U.S. Prescription Drug Market Share Reports.
- FDA. (2022). Drug Approval Data.
- Centers for Medicare & Medicaid Services. (2022). Rebate and formulary policies.
- EvaluatePharma. (2023). Pharmaceutical pricing and projections.
